This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Oct;76(20):10577; author reply 10578.

doi: 10.1128/jvi.76.20.10577-10578.2002.

Synergy determination issues

PMID: 12239339
PMCID: PMC136565
DOI: 10.1128/jvi.76.20.10577-10578.2002

Comment

Synergy determination issues

Ting-Chao Chou. J Virol. 2002 Oct.

. 2002 Oct;76(20):10577; author reply 10578.

doi: 10.1128/jvi.76.20.10577-10578.2002.

Author

PMID: 12239339
PMCID: PMC136565
DOI: 10.1128/jvi.76.20.10577-10578.2002

No abstract available

PubMed Disclaimer

Comment on

Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F, Nádas A, Gorny MK, Zolla-Pazner S. Verrier F, et al. J Virol. 2001 Oct;75(19):9177-86. doi: 10.1128/JVI.75.19.9177-9186.2001. J Virol. 2001. PMID: 11533181 Free PMC article.

Similar articles

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
Buchbinder A, Zolla-Pazner S, Karwowska S, Gorny MK, Burda ST. Buchbinder A, et al. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1395. doi: 10.1089/aid.1992.8.1395. AIDS Res Hum Retroviruses. 1992. PMID: 1466965 No abstract available.
Is there a neutralization epitope in the second conserved domain of HIV-1 envelope protein?
Ronco J, Charbit A, Dedieu JF, Mancini M, Michel ML, Henin Y, O'Callaghan D, Kaczorek M, Girard M, Hofnung M. Ronco J, et al. AIDS Res Hum Retroviruses. 1991 Jan;7(1):1-2. doi: 10.1089/aid.1991.7.1. AIDS Res Hum Retroviruses. 1991. PMID: 1707638 No abstract available.
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins.
Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J, Posner MR, Katinger H, Barbas CF 3rd, Burton DR, Chou TC, Ruprecht RM. Li A, et al. AIDS Res Hum Retroviruses. 1997 May 20;13(8):647-56. doi: 10.1089/aid.1997.13.647. AIDS Res Hum Retroviruses. 1997. PMID: 9168233
Antibody neutralization of human immunodeficiency virus type 1 (HIV-1).
Schønning K. Schønning K. APMIS Suppl. 2003;(111):1-42. APMIS Suppl. 2003. PMID: 12739253 Review. No abstract available.
The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
Parren PW, Moore JP, Burton DR, Sattentau QJ. Parren PW, et al. AIDS. 1999;13 Suppl A:S137-62. AIDS. 1999. PMID: 10885772 Review. No abstract available.

See all similar articles

Cited by

Metformin and oxyphotodynamic therapy as a novel treatment approach for triple-negative breast cancer.
Pei X, Wang X, Xian J, Mi J, Gao J, Li X, Li Z, Yang M, Bi L, Yan Y, Lv W, Jin H. Pei X, et al. Ann Transl Med. 2020 Sep;8(18):1138. doi: 10.21037/atm-20-5704. Ann Transl Med. 2020. PMID: 33240987 Free PMC article.
Statistical determination of synergy based on Bliss definition of drugs independence.
Demidenko E, Miller TW. Demidenko E, et al. PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019. PLoS One. 2019. PMID: 31765385 Free PMC article.
Multifunctional Nanoparticles as Radiosensitizers to Overcome Hypoxia-Associated Resistance in Cancer Radiotherapy.
Chen MH, Yiu HP, Wang YC, Liu TY, Li C. Chen MH, et al. Nanomaterials (Basel). 2024 Dec 29;15(1):37. doi: 10.3390/nano15010037. Nanomaterials (Basel). 2024. PMID: 39791794 Free PMC article.
Comparison of methods for evaluating drug-drug interaction.
Zhao L, Au JL, Wientjes MG. Zhao L, et al. Front Biosci (Elite Ed). 2010 Jan 1;2(1):241-9. doi: 10.2741/e86. Front Biosci (Elite Ed). 2010. PMID: 20036874 Free PMC article.

References

1. Chou, T.-C. 1974. Relationships between inhibition constants and fractional inhibitions in enzyme-catalyzed reactions with different numbers of reactants, different reactions mechanisms, and different types of mechanisms of inhibition. Mol. Pharmacol. 10:235-247. - PubMed
1. Chou, T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, San Diego, Calif.
1. Chou, T.-C., and P. Talalay. 1977. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252:6438-6442. - PubMed
1. Chou, T.-C., and P. Talalay. 1981. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:207-216. - PubMed
1. Chou, T.-C., and P. Talalay. 1987. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents, p. 37-64. In K. R. Harrap and T.A. Connors (ed.), New avenues in developmental cancer chemotherapy, Bristol-Myers Symposium series. Academic Press, New York, N.Y.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database